High-density lipoprotein cholesterol level is associated with fibrous cap thickness in acute coronary syndrome

Circulation Journal

Volumn 77, Issue 12, 2013, Pages 2982-2989

  Ozaki, Yuichi ^a   Tanaka, Atsushi ^a   Komukai, Kenichi ^a   Ishibashi, Kohei ^a   Tanimoto, Takashi ^a   Kitabata, Hironori ^a   Ino, Yasushi ^a   Kubo, Takashi ^a   Imanishi, Toshio ^a   Akasaka, Takashi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Acute coronary syndrome; Fibrous cap thickness; High density lipoprotein cholesterol; Optical coherence tomography

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CLOPIDOGREL; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOSORBIDE DINITRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; AGED; ARTERY DISEASE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD CLOT LYSIS; BLOOD SAMPLING; CORONARY ARTERY DISEASE; GUIDING CATHETER; HUMAN; IMAGING; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTOR; STENT; THIN CAP FIBROATHEROMA;

ACUTE CORONARY SYNDROME; AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84888250533     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0512     Document Type: Article

References (39)

1. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfeld M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocar-dial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
4. Downs JR, Clearfeld M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AF-CAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
6. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364.
7. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Effcacy and safety of cholesterol-lowering treatment: Pro spective meta-analysis of data from 90,056 participants in 14 ran domised trials of statins. Lancet 2005; 366: 1267-1278.
8. Kones R. Primary prevention of coronary heart disease: Integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther 2011; 5: 325-380.
9. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, et al. Effect of pravastatin on coronary disease events in subgroups defned by coronary risk factors: The Prospective Pravastatin Pooling Project. Circulation 2000; 102: 1893-1900.
10. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124 (Suppl): S11-S20.
11. Curb JD, Abbott RD, Rodriguez BL, Masaki K, Chen R, Sharp DS, et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 2004; 45: 948-953.
12. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. Coronary heart disease prediction from lipoprotein choles terol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Com munities (ARIC) Study. Circulation 2001; 104: 1108-1113.
13. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-714.
14. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823-828.
15. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297: 499-508.
16. von Birgelen C, Hartmann M, Mintz GS, Baumgart D, Schmermund A, Erbel R. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (> or =12 months) follow-up intravascular ultrasound. Circulation 2003; 108: 2757-2762.
17. Kimura T, Itoh T, Fusazaki T, Matsui H, Sugawara S, Ogino Y, et al. Low-density lipoprotein-cholesterol/high-density lipoprotein-cho-lesterol ratio predicts lipid-rich coronary plaque in patients with coronary artery disease: Integrated-backscatter intravascular ultrasound study. Circ J 2010; 74: 1392-1398.
18. Kato M, Dote K, Naganuma T, Sasaki S, Ueda K, Okita M, et al. Clinical predictors of culprit plaque rupture assessed on intravascular ultrasound in acute coronary syndrome. Circ J 2010; 74: 1936-1942.
19. Jang IK, Bouma BE, Kang DH, Park SJ, Park SW, Seung KB, et al. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: Comparison with intravascular ultrasound. J Am Coll Cardiol 2002; 39: 604-609.
20. Kataiwa H, Tanaka A, Kitabata H, Imanishi T, Akasaka T. Safety and usefulness of non-occlusion image acquisition technique for optical coherence tomography. Circ J 2008; 72: 1536-1537.
21. Ozaki Y, Kitabata H, Tsujioka H, Hosokawa S, Kashiwagi M, Ishibashi K, et al. Comparison of contrast media and low-molecular-weight dextran for frequency-domain optical coherence tomography. Circ J 2012; 76: 922-927.
22. Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: A report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol 2012; 59: 1058-1072.
23. Ozaki Y, Tanaka A, Tanimoto T, Kitabata H, Kashiwagi M, Kubo T, et al. Thin-cap fbroatheroma as high-risk plaque for microvascular obstruction in patients with acute coronary syndrome. Circ Cardiovasc Imaging 2011; 4: 620-627.
24. Tanaka A, Imanishi T, Kitabata H, Kubo T, Takarada S, Tanimoto T, et al. Morphology of exertion-triggered plaque rupture in patients with acute coronary syndrome: An optical coherence tomography study. Circulation 2008; 118: 2368-2373.
25. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-1310.
26. Gordon DJ, Rifkind BM. High-density lipoprotein: The clinical implications of recent studies. N Engl J Med 1989; 321: 1311-1316.
27. Genest J Jr, Marcil M, Denis M, Yu L. High density lipoproteins in health and in disease. J Investig Med 1999; 47: 31-42.
28. Stein O, Stein Y. Atheroprotective mechanisms of HDL. Atherosclerosis 1999; 144: 285-301.
29. von Eckardstein A, Assmann G. Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? Curr Opin Lipidol 2000; 11: 627-637.
30. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol effux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364: 127-135.
31. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
32. Otsuka F, Hibi K, Kusama I, Endo M, Kosuge M, Iwahashi N, et al. Impact of statin pretreatment on the incidence of plaque rupture in ST-elevation acute myocardial infarction. Atherosclerosis 2010; 213: 505-511.
33. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-372.
34. Kashiwagi M, Tanaka A, Kitabata H, Tsujioka H, Kataiwa H, Komukai K, et al. Feasibility of noninvasive assessment of thin-cap fbroath-eroma by multidetector computed tomography. JACC Cardiovasc Imaging 2009; 2: 1412-1419.
35. Kashiwagi M, Tanaka A, Kitabata H, Tsujioka H, Matsumoto H, Arita Y, et al. Relationship between coronary arterial remodeling, fbrous cap thickness and high-sensitivity C-reactive protein levels in patients with acute coronary syndrome. Circ J 2009; 73: 1291-1295.
36. Alwaili K, Bailey D, Awan Z, Bailey SD, Ruel I, Hafane A, et al. The HDL proteome in acute coronary syndromes shifts to an infam-matory profle. Biochim Biophys Acta 2012; 1821: 405-415.
37. Kubo T, Tanaka A, Kitabata H, Ino Y, Tanimoto T, Akasaka T. Application of optical coherence tomography in percutaneous coronary intervention. Circ J 2012; 76: 2076-2083.
38. Pu J, Mintz GS, Brilakis ES, Banerjee S, Abdel-Karim AR, Maini B, et al. In vivo characterization of coronary plaques: Novel fndings from comparing greyscale and virtual histology intravascular ultrasound and near-infrared spectroscopy. Eur Heart J 2012; 33: 372-383.
39. Kato K, Yonetsu T, Kim SJ, Xing L, Lee H, McNulty I, et al. Non-culprit plaques in patients with acute coronary syndromes have more vulnerable features compared with those with non-acute coronary syndromes: A 3-vessel optical coherence tomography study. Circ Cardiovasc Imaging 2012; 5: 433-440.